Related references
Note: Only part of the references are listed.Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease
Nerea Martin-Gutierrez et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2022)
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
Shintaro Sagami et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars
Rishi J. Desai et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Stephanie L. Ho et al.
BIODRUGS (2020)
Emerging treatments for inflammatory bowel disease
Karl Hazel et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2019)
Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Nam Hee Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
Byong Duk Ye et al.
LANCET (2019)
Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
THERAPEUTIC DRUG MONITORING (2019)
Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
M. Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2019)
An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
Mahmoud Ahmed Ebada et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2019)
Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade
Akos Ilias et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes
Nikolas Plevris et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study
Nicolas Petitdidier et al.
DIGESTIVE AND LIVER DISEASE (2019)
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa et al.
INTESTINAL RESEARCH (2019)
Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
Cristian Gheorghe et al.
JOURNAL OF DRUG ASSESSMENT (2019)
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
Maria Fernanda Guerra Veloz et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population
Marte L. Hoivik et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience
Raguprakash Ratnakumaran et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2018)
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
Maria Fernanda Guerra Veloz et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2018)
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
Maria Fernanda Guerra Veloz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
Anne S. Strik et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
Yoshiya Tanaka et al.
MODERN RHEUMATOLOGY (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases
Y. Komaki et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical Outcomes Following a Switch from RemicadeA® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
Lisa J. T. Smits et al.
JOURNAL OF CROHNS & COLITIS (2016)
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Klaudia Farkas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
Yun-Seong Kang et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial
Koji Yoshida et al.
INFLAMMATORY BOWEL DISEASES (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Long-term Treatment of Rectovaginal Fistulas in Crohn's Disease: Response to Infliximab in the ACCENT II Study
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
